Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[590-S].

H Furue

    Gan No Rinsho. Japan Journal of Cancer Clinics
    |May 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    590-S, a 5-fluorouracil derivative, demonstrates good absorption, high drug levels, and low toxicity in studies. It shows excellent tumor inhibition and a broad anticancer spectrum with a maximum tolerated dose of 750-800 mg/m2.

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Processing of CD109 by furin and its role in the regulation of TGF-beta signaling.

    Oncogene·2010
    Same author

    Responses to 5-HT in morphologically identified neurons in the rat substantia gelatinosa in vitro.

    Neuroscience·2009
    Same author

    Action of neuropeptide Y on nociceptive transmission in substantia gelatinosa of the adult rat spinal dorsal horn.

    Neuroscience·2005
    Same author

    [Anti-nociceptive effect of calcitonin on chronic pain associated with osteoporosis].

    Clinical calcium·2005
    Same author

    Functional reorganization of the spinal pain pathways in developmental and pathological conditions.

    Novartis Foundation symposium·2004
    Same author

    Analysis of receptive fields revealed by in vivo patch-clamp recordings from dorsal horn neurons and in situ intracellular recordings from dorsal root ganglion neurons.

    Life sciences·2004
    Same journal

    [A neuron-specific enolase (NSE) positive leiomyosarcoma].

    Gan no rinsho. Japan journal of cancer clinics·1990
    Same journal

    [A case of synchronous multiple primary cancers of the stomach and kidney].

    Gan no rinsho. Japan journal of cancer clinics·1990
    Same journal

    [A case of multiple peripheral pulmonary carcinoids showing a diffuse lung disease synchronously associated with sigmoid colon cancer].

    Gan no rinsho. Japan journal of cancer clinics·1990
    Same journal

    [A well differentiated fibrosarcoma arising in left neck region].

    Gan no rinsho. Japan journal of cancer clinics·1990
    Same journal

    [A giant struma histologically confirmed as a medullary carcinoma with multiple systemic bone metastasis].

    Gan no rinsho. Japan journal of cancer clinics·1990
    Same journal

    [Problems associated with radical neck dissection in patients with tongue carcinoma: four cases of stage I tongue carcinoma that recurred in the cervical area after the dissection].

    Gan no rinsho. Japan journal of cancer clinics·1990
    See all related articles

    Area of Science:

    • Oncology
    • Pharmacology
    • Medicinal Chemistry

    Context:

    • 590-S is a novel derivative of 5-fluorouracil.
    • Experimental studies have investigated its pharmacological properties.

    Purpose:

    • To evaluate the characteristics and preliminary safety of 590-S.
    • To determine the maximum tolerated dose (MTD) and toxicity profile.

    Summary:

    • 590-S exhibits favorable oral absorption and achieves high plasma concentrations of 5-fluorouracil.
    • The compound demonstrates rapid clearance, low toxicity, potent tumor inhibition, and a broad anticancer spectrum.
    • Phase I studies suggest an MTD of 750-800 mg/m2/day with mild gastrointestinal toxicities and no central nervous system toxicity observed.

    Impact:

    • 590-S shows promise as a well-tolerated anticancer agent with broad-spectrum activity.
    • Further clinical development may be warranted based on its favorable pharmacokinetic and toxicity profile.